Business acquisition - Narrative (Details) - USD ($) $ in Thousands		1 Months Ended				3 Months Ended	9 Months Ended	10 Months Ended
	Dec. 01, 2021	Jan. 31, 2023	Dec. 31, 2022	Jan. 31, 2022	Dec. 31, 2021	Jun. 30, 2023	Jun. 30, 2023	Sep. 30, 2022
Abveris
Business Acquisition [Line Items]
Fair value of consideration transferred	$ 102,645
Cash	$ 9,467
Equity (in shares)	759,601
Company common stock	$ 72,514					$ 1,800
Options consideration	6,400
Contingent consideration	8,500
Holdback Liabilities	12,800
Net working capital adjustment	$ (674)
Contingent consideration, shares issuable up to (in shares)	334,939
Indemnity holdbacks period	18 months
Contingent consideration (in shares)						104,727,000
Indemnity holdback consideration	$ 12,500
Adjustment holdback shares (in shares)	3,416					538	538
Adjustment holdback options (in shares)	408
Value of adjustment holdback	$ 300
Post combination compensation expenses includes employee stock awards					$ 41,000
Vesting period	2 years
Change in fair value during the period							$ 5,426	$ 13,471
Abveris | Awards with vesting requirements
Business Acquisition [Line Items]
Post combination compensation expenses includes employee stock awards					$ 17,700
Vesting period					2 years
Abveris | Awards without vesting requirements
Business Acquisition [Line Items]
Post combination compensation expenses includes employee stock awards					$ 3,200
Abveris | Performance Shares
Business Acquisition [Line Items]
Post combination compensation expenses includes employee stock awards					$ 20,100
iGenomX
Business Acquisition [Line Items]
Company common stock	$ 66,100	$ 4,100		$ 4,600
Contingent consideration (in shares)			171,551		59,190